Innovative Proteomics Platform Nomic Bio's proprietary nELISA technology enables large-scale, cost-effective protein measurement, making it a compelling partner for pharmaceutical and biotech companies seeking advanced proteomics solutions to accelerate drug discovery and biomarker development.

Recent Funding Growth With a recent Series B funding of $42 million, Nomic Bio is positioned for expansion and upgrades to its proteomics platform, presenting opportunities to collaborate on innovative projects and customize solutions for clients with complex biological data needs.

Data-Driven Insights The company's recent launch of a 1.4 million-data-point cytokine dataset demonstrates its capability to generate and manage large, complex proteomic datasets, making it an attractive partner for organizations requiring high-throughput data analysis and integration.

Strategic Collaborations Partnerships with renowned institutions like the Broad Institute and multi-sector expansion efforts reflect Nomic Bio’s growing influence, offering avenues for co-development and early access to cutting-edge proteomics tools and data.

Market Positioning Operating in a competitive biotech landscape with peers of similar revenue ranges, Nomic Bio’s focus on making proteomics more accessible and routine offers sales opportunities for companies targeting scalable and user-friendly biological measurement technologies.